Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

René Østgård, H Glerup, AG Jurik, Tue W Kragstrup, K. Stengaard-Pedersen, M.L Hetland, K. Hørslev-Petersen, P. Junker, Bent Deleuran

Research output: Contribution to journalLetterResearchpeer-review

Abstract

Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

Original languageEnglish
JournalScandinavian Journal of Rheumatology
Volume46
Issue number6
Pages (from-to)441-445
ISSN0300-9742
DOIs
Publication statusPublished - Nov 2017

Fingerprint

Hepcidins
Antirheumatic Agents
Joint Diseases
Erythropoiesis
Statistical Models
Iron
Placebos

Keywords

  • Adalimumab/therapeutic use
  • Adult
  • Aged
  • Antirheumatic Agents/therapeutic use
  • Arthritis, Rheumatoid/blood
  • Case-Control Studies
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Ferritins/blood
  • Hemoglobins/metabolism
  • Hepcidins/blood
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Receptors, Transferrin/blood
  • Young Adult

Cite this

Østgård, René ; Glerup, H ; Jurik, AG ; Kragstrup, Tue W ; Stengaard-Pedersen, K. ; Hetland, M.L ; Hørslev-Petersen, K. ; Junker, P. ; Deleuran, Bent. / Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. In: Scandinavian Journal of Rheumatology. 2017 ; Vol. 46, No. 6. pp. 441-445.
@article{9f1db638d703481ea352049fd3577a0d,
title = "Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients",
abstract = "Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment na{\"i}ve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.",
keywords = "Adalimumab/therapeutic use, Adult, Aged, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/blood, Case-Control Studies, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Ferritins/blood, Hemoglobins/metabolism, Hepcidins/blood, Humans, Longitudinal Studies, Male, Middle Aged, Randomized Controlled Trials as Topic, Receptors, Transferrin/blood, Young Adult",
author = "Ren{\'e} {\O}stg{\aa}rd and H Glerup and AG Jurik and Kragstrup, {Tue W} and K. Stengaard-Pedersen and M.L Hetland and K. H{\o}rslev-Petersen and P. Junker and Bent Deleuran",
year = "2017",
month = "11",
doi = "10.1080/03009742.2017.1286382",
language = "English",
volume = "46",
pages = "441--445",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Taylor & Francis",
number = "6",

}

Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. / Østgård, René; Glerup, H; Jurik, AG; Kragstrup, Tue W; Stengaard-Pedersen, K.; Hetland, M.L; Hørslev-Petersen, K.; Junker, P.; Deleuran, Bent.

In: Scandinavian Journal of Rheumatology, Vol. 46, No. 6, 11.2017, p. 441-445.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

AU - Østgård, René

AU - Glerup, H

AU - Jurik, AG

AU - Kragstrup, Tue W

AU - Stengaard-Pedersen, K.

AU - Hetland, M.L

AU - Hørslev-Petersen, K.

AU - Junker, P.

AU - Deleuran, Bent

PY - 2017/11

Y1 - 2017/11

N2 - Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

AB - Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

KW - Adalimumab/therapeutic use

KW - Adult

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Rheumatoid/blood

KW - Case-Control Studies

KW - Double-Blind Method

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Ferritins/blood

KW - Hemoglobins/metabolism

KW - Hepcidins/blood

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Receptors, Transferrin/blood

KW - Young Adult

U2 - 10.1080/03009742.2017.1286382

DO - 10.1080/03009742.2017.1286382

M3 - Letter

C2 - 28482738

AN - SCOPUS:85019136713

VL - 46

SP - 441

EP - 445

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -